Advances in Cardiovascular Risk Reduction
Improving treatment for patients with diabetes
Thursday, May 11, 2017
Jointly provided by the NYU Post-Graduate Medical School and the New York Chapter of the American College of Physicians.
NYU Langone Medical Center
550 First Avenue
Alumni Hall, Farkas Auditorium
New York, NY 10016
Reduced Fee *: $95
Cardiologists, endocrinologists, internists, general practice, family practitioners, nurse practitioners, nurses and physician trainees with an interest in the prevention of heart disease.
This one-day course will cover state-of-the-art management of patients with cardiovascular risk factors, with a focus on prevention. The morning session will focus on the latest scientific and clinical advances in the management of diabetes. In addition, the release of updated guidelines in diabetes management will provide state-of-the-art principles that will guide presentations and discussions throughout the morning session. Topics will include recent technological advances in diabetic care, a new algorithm for choice of therapies for T2DM and the management of inpatient diabetics. The role of diabetes nurses and their impact on a medical practice will also be presented. The afternoon session will include an update on platelets, PCSK9, APO C3 and triglycerides. Current strategies for atherosclerosis imaging will be reviewed as well as the clinical management of resistant hypertension.
Each year this course includes a research-oriented presentation that highlights bench-to-bedside relevance. This year the featured research-oriented presentation will focus on the latest research in diabetes expanding our understanding of this complex disease.
Ten (10) half-hour presentations will be given. Attendees will participate in a lunchtime hour-long case conference with challenging cases in cardiovascular disease risk reduction. Course participants are given the opportunity to submit questions to the featured speakers and panel members. The course will include morning and afternoon panel discussion segments (45 min each) in which the questions from the audience are answered and debated among expert panel members.
At the conclusion of this activity, participants should be able to:
- Describe novel technological advances in diabetic care and how they may improve patient outcomes
- Discuss best practices for the inpatient management of diabetics
- Describe the role and benefits of incorporating diabetes nurses in an outpatient private practice setting
- Summarize recent changes to the diabetes management algorithm, including modifications based on cardiovascular risk factors such as dyslipidemia and high blood pressure
- Describe how PCSK9 modulates LDL levels and how PCSK9 expression is affected by statin treatment
- Summarize the role of aspirin in preventing cardiovascular events and their efficacy and safety in light of recent clinical trials
- Incorporate noninvasive testing modalities for atherosclerosis in assessing risk for development as well as identification of subclinical disease
- Describe recent APOC3 studies and how the results of these studies have elucidated the role of APOC3 on triglyceride levels and CAD risk
Statement of Need
Novel technological advances in diabetic care can facilitate the management of this complex disease. Newer diabetes technologies have emerged that may improve the daily management of the disease. The management of a hospitalized diabetic patient requires the careful coordination of a multidisciplinary team including physicians, nurses, and dietitians. New guidelines published by the American Diabetes Association (2016) provide updated recommendations on how to most effectively manage the inpatient diabetic to optimize patient outcomes. Over 29.1 million Americans have diabetes and many suffer or are at risk for cardiovascular comorbidities such as dyslipidemia and hypertension. Diabetes nurses provide essential care for this complex disease. Establishing the role of the diabetes nurse and incorporating their expertise within the interdisciplinary team in the outpatient private practice setting may improve patient engagement and management of diabetic self-care. In January 2016, the American Association of Clinical Endocrinologists and the American College of Endocrinology released “The Comprehensive Type 2 Diabetes Management Algorithm”. The guide provides updated treatment algorithms including specific guidance on how to treat the atherosclerotic cardiovascular disease patient. This activity will provide an overview of the new recommendations. Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors were approved by the FDA in 2015 for lipid lowering. Two drugs are currently approved and a third drug is currently in phase 3 clinical trials. Clinical trials are also underway studying the effectiveness and safety of PCSK9 in the diabetic population. New studies continue to shed light on this novel avenue of treatment. Aspirin has been well studied as a tool for preventing cardiovascular disease. Recent studies suggest that daily aspirin may play a role in cancer prevention. In April 2016, the U.S. Preventive Service recommended aspirin for the prevention of cardiovascular disease and colorectal cancer. In addition, recently released ACC/AHA guidelines provide updated recommendations on dual antiplatelet therapy. This activity will review current concepts and options in anti-platelet therapy. Atherosclerotic imaging can provide physicians with useful information in assessing a person’s risk of developing atherosclerotic disease. New technological advances and recent studies will be reviewed. High triglyceride levels are associated with an increased risk for cardiovascular disease. Studies have shown that mutations in the Apolipoprotein C3 (APOC3) gene are associated with lower triglyceride levels. Phase 3 clinical trials are currently underway testing an investigational drug that targets the APOC3 protein to treat hypertriglyceridemia.
CME Accreditation Statement
The NYU Post-Graduate Medical School is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the NYU Post-Graduate Medical School, the NY Chapter American College of Physicians.
Credit Designation Statement
The NYU Post-Graduate Medical School designates this live activity for a maximum of 7.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The program has been assigned 6.25 continuing nursing education contact hours.
The NYU Meyers College of Nursing Center for Continuing Education in Nursing is accredited as a provider of continuing nursing education by the American Nurses’ Credentialing Center’s Commission on Accreditation.
In order to request a refund, you must email email@example.com no later than 14 days prior to the first day of the course. An administrative fee of $75 will be deducted from your refund. Cancellations or no-shows after this date are not eligible for a refund. If your registration fee is $75 or less, then no refunds are available. Registration is non-transferable.
Course Cancellation Policy
If a course is cancelled due to inclement weather, insufficient enrollment or any other reason, NYU PGMS will refund registration fees in full. NYU PGMS will provide at least two weeks advance notice if cancelling due to insufficient enrollment and as soon as possible in all other circumstances. NYU PGMS is not responsible for any airfare, hotel or other non-cancellable costs incurred by the registrant.